Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin in ALS dose-finding and safety study
2011-001329-26Phase 2Active
- Sponsor
- Carlo Besta Neurological Institute
- Start
- Nov 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of erythropoietin in amyotrophic lateral sclerosis (ALS) (4 arms), sponsored by Carlo Besta Neurological Institute. Started Nov 2011; status: active.
02
Drugs
erythropoietin
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2011-001329-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001329-26.